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Research
AbstrACt
Objectives While older age and ill health are known 
to be associated with polypharmacy, this paper aims 
to identify whether wealth, body mass index (BMI), 
smoking and alcohol consumption are also associated 
with polypharmacy (5–9 prescribed medications) 
and hyperpolypharmacy prevalence (≥10 prescribed 
medications), among older people living in England.
Design Cross-sectional study.
setting The English Longitudinal Study of Ageing Wave 6 
(2012–2013).
Participants 7730 participants aged over 50 years.
Data synthesis Two multivariate models were created. 
HR with corresponding 95% CI, for polypharmacy and 
hyperpolypharmacy, were calculated after adjusting for 
gender, age, wealth, smoking, alcohol consumption, BMI, 
self-rated health and the presence of a chronic health 
condition.
results Lower wealth (lowest wealth quintile vs 
highest wealth quintile, adjusted HR 1.28; 95% CI 1.04 
to 1.69, P=0.02) and obesity (adjusted HR 1.81; 95% CI 
1.53 to 2.15, p<0.01) were significantly associated 
with polypharmacy. Increasing age (50–59 years vs 
70–79 years, adjusted HR 3.42; 95% CI 2.81 to 4.77, 
p<0.01) and the presence of a chronic health condition 
(adjusted HR 2.94; 95% CI 2.55 to 3.39, p<0.01) were also 
associated with polypharmacy. No statistically significant 
association between smoking and polypharmacy (adjusted 
HR 1.06; 95% CI 0.86 to 1.29, P=0.56) was established; 
while, very frequent alcohol consumption (consuming 
alcohol >5 times per week) was inversely associated with 
polypharmacy (never drank alcohol vs very frequently, 
adjusted HR 0.64; 95% CI 0.52 to 0.78, p<0.01). The 
adjusted HR for hyperpolypharmacy was accentuated, 
compared with polypharmacy.
Conclusion This study has identified that lower wealth, 
obesity, increasing age and chronic health conditions 
are significantly associated with polypharmacy 
and hyperpolypharmacy prevalence. The effect 
of these factors, on polypharmacy and especially 
hyperpolypharmacy prevalence, is likely to become 
more pronounced with the widening gap in UK wealth 
inequalities, the current obesity epidemic and the growing 
population of older people. The alcohol findings contribute 
to the debate on the relationship between alcohol 
consumption and health.
IntrODuCtIOn 
Polypharmacy has been discussed extensively 
in the literature and media; however, there 
is no universally accepted definition for the 
practice of prescribing multiple medications 
to one individual.1 At present, polypharmacy 
is commonly defined as ‘the use of five or 
more regular medications’, while hyperpoly-
pharmacy, which is sometimes termed as 
‘excessive polypharmacy’, is defined as ‘the 
use of ten or more regular medications’.2 
Although polypharmacy prevalence has 
increased over the past decade, there are rela-
tively few data about the factors associated 
with polypharmacy and hyperpolypharmacy 
in primary care.3 
Previous studies have shown that increasing 
age and the presence of chronic conditions 
are significantly associated with an increase in 
polypharmacy prevalence.4–6 Comparatively 
fewer studies have examined whether socio-
demographic or lifestyle factors, for example, 
wealth and obesity, are associated with poly-
pharmacy. In a study conducted by Haider 
et al,7 no statistically significant association 
between polypharmacy and an individual’s 
strengths and limitations of this study
 ► This cross-sectional study uses medication data, 
from over 7000 older individuals, to identify factors 
which are associated with polypharmacy prevalence 
in primary care.
 ► In the analysis, a large number of covariates were 
used to minimise the impact of confounding factors.
 ► Participants were asked to self-report the information 
about their prescribed medication usage. To verify 
their responses, participants were asked to show 
their medication containers to the interviewer.
 ► Smoking and alcohol consumption data were also 
collected by asking participants to self-report. This 
relies on accurate and truthful information recall to 
prevent bias.
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socioeconomic status was established. The findings from 
a study by Rajska-Neumann et al8 revealed that there was 
no statistically significant difference in polypharmacy 
prevalence between smokers and non-smokers; whereas 
a statistically significant inverse relationship between 
alcohol consumption and the concomitant administra-
tion of medications was detected by Wong et al.9 Finally, 
when Bueno et al10 examined the association between 
polypharmacy and obesity, an adjusted OR revealed that 
obese individuals (body mass index (BMI) ≥30 kg/m2) 
were 1.6 times more likely to be experiencing polyphar-
macy, compared with individuals with a BMI <30 kg/m2. 
To evaluate the relationship between the aforementioned 
factors and polypharmacy prevalence in primary care, a 
large sample study is required.
This study used data from The English Longitudinal 
Study of Ageing (ELSA) as this provided an opportu-
nity to link polypharmacy and hyperpolypharmacy data 
to participants’ personal data. In particular, this study 
aimed to determine whether wealth, BMI, smoking, 
alcohol consumption, age and the presence of chronic 
health conditions are associated with polypharmacy 
(5–9 prescribed medications) and hyperpolypharmacy 
(≥10 prescribed medications) prevalence in a community 
population of older people living in England.
MethOD
sample and participants
A cross-sectional study was conducted using Wave 6 data 
from ELSA. Data collection took place between May 
2012 and June 2013, from a representative sample of the 
English population who were aged 50 years or above.
Since ELSA began in 2002, participants have been asked 
to provide personal information about their household 
finances, health status, lifestyle choices and social inter-
actions, on a biannual basis. In Wave 6, information from 
10 601 participants was collected, which included 9169 
‘core’ participants. Members were considered ‘core’ if they 
were aged over 50 years old at the time of study enrolment 
and living at private residential addresses in England.11 
Eight thousand and fifty-four nurse visits were completed at 
Wave 6, of which 7730 were carried out with core members. 
This latter group is the focus of the current study.11
Patient involvement and ethics
All participants were required to provide informed written 
consent.12 All ELSA data are anonymous and freely acces-
sible from the UK Data Service Discover.13 Only data 
contained within the ELSA database were included in the 
analyses. No patients were involved in the development of 
the research question, study design or interpretation of the 
data in this study.
Data collection
Face-to-face interviews
The face-to-face interviews were conducted by trained 
interviewers, who asked participants to provide 
information about their current lifestyle choices, 
including smoking habits and alcohol consumption 
over the past 12 months. Smoking status was recorded as 
current smoker or non-smoker; whereas, the frequency 
of alcohol consumption over the past year was recorded 
as never, rarely, frequently or very frequently.14 Rarely 
was defined as drinking alcohol less than two times in 
a month. Frequently was defined as drinking alcohol 
between one and four times a week; while, very frequently 
was defined as drinking alcohol at least five times a week.
Participants were also asked to describe their current 
health status. Participants could select one of the following 
options: ‘excellent, very good, good, fair or poor’.15 These 
responses were converted into a two-level variable: good/
fair and poor, with good/fair health status being the sum 
of responses ranging from ‘excellent’ to ‘fair’. In a subse-
quent question, participants were asked whether they had 
any chronic health conditions. Participants could answer 
this question with either yes or no.15
Finally, participants were asked to provide information 
about their household income, including information 
about their employment status, personal finances, assets, 
pensions and other benefits. Participant pension data 
were excluded when wealth index scores were calculated. 
Based on their wealth index scores, participants were allo-
cated to one of five wealth quintiles. Quintile 1 was the 
most affluent, while quintile 5 was the poorest.
Questionnaire
After completion of the face-to-face interview, participants 
were asked to complete a paper-based questionnaire. The 
questionnaire was designed to obtain further information 
about the participants’ living arrangements, health status, 
lifestyle choices and social interactions.16
Nurse visit
The nurse visits took place in the participant’s home. At 
the beginning of the visit, the nurse recorded informa-
tion about participant demographics and their current 
prescribed medications. Prescribed medication formu-
lations were defined by the nurses as ‘pills, syrups, oint-
ments, inhalers or injections’.17 If a participant reported 
taking one or more prescribed medications, the nurse 
sought their permission to record the name of their 
medication, in addition to seeing its container. The 
nurse determined current medication usage by asking 
the participant to confirm whether they had taken or 
used each reported medicine within the last 7 days.17 
A maximum of 27 prescribed medications could be 
recorded for each participant. Medication information 
was coded by the nurse, according to the British National 
Formulary (BNF) (edition 61) chapter and subsection.
During the latter part of the visit, the nurse conducted 
a physical examination and recorded information about 
the participant’s blood pressure, grip strength, height, 
weight and lung function.17 Using a participant’s height 
and weight data, it was possible to calculate their BMI. 
A BMI <18.5 kg/m2 was recorded as underweight, a BMI 
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value between 18.5 kg/m2 and 24.9 kg/m2 was considered 
to be normal weight; whereas, a BMI of 25.0–29.9 kg/m2 
was recorded as overweight and a BMI ≥30 kg/m2 was 
recorded as obese.
Inclusion criteria
All participants must have completed a face-to-face inter-
view, a paper-based questionnaire and received a nurse 
visit during ELSA Wave 6 to meet the inclusion criteria 
for this study.18
Defining polypharmacy and hyperpolypharmacy
Polypharmacy was defined as the concurrent use of 5–9 
currently prescribed medications, while hyperpolyphar-
macy was defined as the concurrent use of ≥10 currently 
prescribed medications. These definitions have been 
used previously in other population-based studies.3 19
Data analysis
Initially, descriptive statistics were used to summarise 
the prevalence of polypharmacy and hyperpolyphar-
macy among participants. These data were subsequently 
stratified according to participant demographics. In the 
second part of the analysis, a bivariate model was used 
to assess the relationship between polypharmacy and 
the following independent variables: frequent alcohol 
consumption, increasing age, lower wealth, female sex, 
smoking, raised BMI, poor self-rated health and the pres-
ence of a chronic health condition. Bivariate correlations 
between other covariates were also examined. Findings 
were presented as Pearson’s correlation coefficients (r). 
The strength of each correlation was considered and 
described as either strong (1.00–0.50), moderate (0.49–
0.30) or weak (0.29–0.10).20
In the final part of the analysis, two multivariate models 
were created to identify associations between participant 
characteristics and polypharmacy prevalence. Based on 
previous work by Peduzzi et al,21 the minimum sample size 
required for the first multivariate model (polypharmacy) 
was 333; while the minimum sample size required for 
the second multivariate model (hyperpolypharmacy) was 
1250. In both models, ill health was controlled for by using 
participants taking between one and four prescribed medi-
cations. This group of participants formed the control 
group. Participants taking no prescribed medications were 
excluded from this part of the analysis. In the first model, 
participants taking 5–9 medications were compared with 
the control group (1–4 prescribed medications). In the 
second model, participants taking ≥10 medications were 
compared with the control group (1–4 prescribed medica-
tions). HRs with corresponding 95% CI, for polypharmacy 
and hyperpolypharmacy, were calculated after adjusting 
for covariates. The following factors were considered as 
covariates: gender, age, wealth, smoking, alcohol consump-
tion, BMI, self-rated health and the presence of a chronic 
health condition. Missing data were coded as ‘missing’ 
and presented as a separate category in the multivariate 
models. The data generated from the models were consid-
ered to be statistically significant if P<0.05. All data analyses 
were undertaken using SPSS V.24.0.
results
Participant characteristics
A total of 7730 participants’ data from ELSA Wave 6 were 
analysed. Participant characteristics are presented in table 1. 
The mean age of participants in Wave 6 was 67.6 years, and 
55.4% (n=4282/7730) of the sample were women. Overall, 
24.1% (n=1862/7725) of the participants received poly-
pharmacy and 6.4% (n=494/7725) were receiving hyper-
polypharmacy (table 1). The proportion of individuals 
receiving polypharmacy and hyperpolypharmacy increased 
steadily with age. However, the prevalence of polypharmacy 
and hyperpolypharmacy in men and women was similar 
(table 1).
Table 1 Polypharmacy versus patient characteristics
No medications 1–4 medications 5–9 medications ≥10 medications
Participant characteristics Polypharmacy Hyperpolypharmacy
  All participants (n=7725) 23.8% 45.7% 24.1% 6.4%
  Missing medication data (n=5)
Age (years)
  50–59 (n=1695) 43.2% 42.4% 11.7% 2.7%
  60–69 (n=3012) 26.6% 49.2% 19.6% 4.6%
  70–79 (n=2114) 11.8% 45.9% 33.1% 9.2%
  80+ (n=909) 6.4% 39.6% 41.3% 12.7%
Gender
  Male (n=3448) 24.9% 44.6% 24.4% 6.1%
  Female (n=4282) 22.9% 46.6% 23.9% 6.6%
Chronic health condition
  Yes (n=4289) 9.6% 44.5% 35.2% 10.7%
  No (n=3441) 41.6% 47.1% 10.3% 1.0%
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Overall, 35.2% (n=1509/4289) of participants who 
reported having a chronic health condition were receiving 
polypharmacy; whereas, 10.7% (n=459/4289) were 
receiving hyperpolypharmacy. Only 10.3% (n=353/3441) 
and 1.0% (n=35/3441) of participants with no chronic 
health conditions, received polypharmacy and hyperpoly-
pharmacy, respectively (table 1).
In a bivariate model, moderate positive correlations 
were detected between polypharmacy and the following 
variables: the presence of a chronic health condition, 
poor self-rated health and increasing age. A weak positive 
correlation between polypharmacy and a high BMI was 
established. Similarly, there was a weak positive correla-
tion between lower wealth and polypharmacy. No correla-
tions between gender and polypharmacy, and smoking 
and polypharmacy, were established. However, there was 
a weak negative correlation between polypharmacy and 
frequent alcohol consumption. All bivariate correlations 
are presented in figure 1. Bivariate correlations between 
other covariates were also examined, and data are avail-
able in online supplementary table 1.
To determine whether other variables are associated 
with polypharmacy and hyperpolypharmacy, the results 
from the two multivariate models (polypharmacy-1 and 
hyperpolypharmacy-2) were analysed and presented in 
tables 2 and 3, respectively.
examining the association between age and polypharmacy
In both models, increasing age was associated with poly-
pharmacy and hyperpolypharmacy. For participants aged 
between 70 years and 79 years, the adjusted HR for poly-
pharmacy was 3.42 (2.81 to 4.77, p<0.01) (table 2). This 
value increased to 4.52 (3.58 to 5.70, p<0.01) in participants 
aged ≥80 years old (table 2). Similarly, the adjusted HRs 
for hyperpolypharmacy increased from 4.11 (2.77 to 6.09, 
p<0.01) in participants aged between 70 years and 79 years 
to 5.94 (3.79 to 9.29, p<0.01) in participants aged ≥80 years 
old (table 3). All findings were statistically significant.
examining the association between the presence of a chronic 
health condition and polypharmacy
The adjusted HR for polypharmacy and the presence of a 
chronic health condition was 2.94 (2.55 to 3.39, p<0.01) 
(table 2), whereas for hyperpolypharmacy and the pres-
ence of a chronic health condition, it was 5.30 (3.63 to 
7.73, p<0.01) (table 3). In both models, statistically signif-
icant results were generated.
examining the association between wealth and polypharmacy
The adjusted HR for polypharmacy increased from 1.08 
(0.9 to 1.31, P=0.37) in wealth quintile 2 to 1.28 (1.04 to 
1.69, P=0.02) in wealth quintile 5 (table 2). Similarly, the 
adjusted HR for hyperpolypharmacy increased from 1.41 
(0.93 to 2.13, P=0.11) in wealth quintile 2 to 2.04 (1.34 
Figure 1 Bivariate correlations between polypharmacy and covariates. BMI, body mass index.
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to 3.11, p<0.01) in wealth quintile 5 (table 3). In both 
models, statistically significant differences in adjusted 
HRs for polypharmacy and hyperpolypharmacy were 
detected in the lower wealth quintiles (quintile 4 and 5).
examining the association between bMI and polypharmacy
In underweight participants, the adjusted HR for poly-
pharmacy was 0.93 (0.5 to 1.74, P=0.83) (table 2); whereas, 
the adjusted HRs for polypharmacy in participants who 
Table 2 Model 1: independent variables for polypharmacy (5–9 medications, n=2356) versus no polypharmacy (1–4 
medications, n=3532)
Independent variables Adjusted HR
95% CI
Significance Lower Upper
Age (years)
50–59 (reference) (n=963) 1
  60–69 (n=2210) 1.66 1.37 2.01 <0.01
  70–79 (n=2344) 3.42 2.81 4.77 <0.01
  80+ (n=371) 4.52 3.58 5.70 <0.01
Gender
Male (reference) (n=2588) 1
  Female (n=3300) 0.92 0.81 1.04 0.21
Chronic health condition
No (reference) (n=2008) 1
  Yes (n=3879) 2.94 2.55 3.39 <0.01
  Missing chronic health condition data (n=1)
Self-rated health
Self-rated health: good (reference) (n=3907) 1
  Self-rated health: poor (n=1978) 2.98 2.61 3.4 <0.01
  Missing self-rated health data (n=3)
Wealth
Wealth: quintile 1 (wealthiest) (reference) (n=1237) 1
  Wealth: quintile 2 (n=1244) 1.08 0.9 1.31 0.37
  Wealth: quintile 3 (n=1196) 1.13 0.93 1.37 0.19
  Wealth: quintile 4 (n=1190) 1.23 1.02 1.5 0.03
  Wealth: quintile 5 (poorest) (n=921) 1.28 1.04 1.69 0.02
  Missing wealth data (n=100)
BMI (kg/m2)
  <18.5: underweight (n=54) 0.93 0.5 1.74 0.83
18.5–24.9: normal (reference) (n=1313) 1
  25.0–29.9: overweight (n=2272) 1.13 0.96 1.33 0.13
  ≥30: obese (n=1930) 1.81 1.53 2.15 <0.01
  Missing BMI data (n=319)
Current smoking habits since last ELSA interview
Non-smoker (reference) (n=3153) 1
  Smoker (n=650) 1.06 0.86 1.29 0.56
  Missing smoking data (n=2085)
Alcohol consumption in past 12 months
Never (reference) (n=792) 1
  Rarely (n=930) 0.76 0.61 0.94 0.01
  Frequently (n=1797) 0.65 0.53 0.79 <0.01
  Very frequently (n=1791) 0.64 0.52 0.78 <0.01
  Missing alcohol consumption data (n=578)
BMI, body mass index; ELSA, The English Longitudinal Study of Ageing.
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were overweight or obese were 1.13 (0.96 to 1.33, P=0.13) 
and 1.81 (1.53 to 2.15, p<0.01), respectively (table 2). 
Adjusted HRs for hyperpolypharmacy produced similar 
results. In underweight participants, the adjusted HR 
for hyperpolypharmacy decreased to 0.88 (0.26 to 
2.95, P=0.83) (table 3); whereas, the adjusted HR for 
hyperpolypharmacy in overweight participants was 1.38 
(0.98 to 1.95, P=0.07) increasing substantially to 2.28 
(1.63 to 3.21, p<0.01) in obese participants (table 3). 
Only the adjusted HRs for polypharmacy and hyperpoly-
pharmacy, in relation to obesity, produced statistically 
significant results.
Table 3 Model 2: independent variables for hyperpolypharmacy (≥10 medications, n=494) versus no polypharmacy (1–4 
medications, n=3532)
Independent variables Adjusted HR
95% CI
Significance  Lower Upper
Age (years)
50–59 (reference) (n=765) 1
  60–69 (n=1620) 1.79 1.21 2.64 <0.01
  70–79 (n=1444) 4.11 2.77 6.09 <0.01
  80+ (n=197) 5.94 3.79 9.29 <0.01
Gender
Male (reference) (n=1748) 1
  Female (n=2278) 0.94 0.71 1.15 0.41
Chronic health condition
No (reference) (n=1656) 1
  Yes (n=2370) 5.30 3.63 7.73 <0.01
Self-rated health
Self-rated health: good (reference) (n=2944) 1
  Self-rated health: poor (n=1081) 6.69 5.21 8.58 <0.01
  Missing self-rated health data (n=1)
Wealth
Wealth: quintile 1 (wealthiest) (reference) (n=907) 1
  Wealth: quintile 2 (n=875) 1.41 0.93 2.13 0.11
  Wealth: quintile 3 (n=797) 1.36 0.90 2.06 0.15
  Wealth: quintile 4 (n=756) 1.75 1.17 2.60 <0.01
  Wealth: quintile 5 (poorest) (n=611) 2.04 1.34 3.11 <0.01
  Missing wealth data (n=80)
BMI (kg/m2)
  <18.5: underweight (n=38) 0.88 0.26 2.95 0.83
18.5–24.9: normal (reference) (n=959) 1
  25.0–29.9: overweight (n=1633) 1.38 0.98 1.95 0.07
  ≥30: obese (n=1205) 2.28 1.63 3.21 <0.01
  Missing BMI data (n=191)
Current smoking habits since last ELSA interview
Non-smoker (reference) (n=2077) 1
  Smoker (n=424) 0.98 0.68 1.39 0.89
  Missing smoking data (n=1525)
Alcohol consumption in past 12 months
Never (reference) (n=489) 1
  Rarely (n=619) 0.70 0.50 0.99 0.05
  Frequently (n=1256) 0.40 0.29 0.56 <0.01
  Very frequently (n=1293) 0.39 0.27 0.55 <0.01
  Missing alcohol consumption data (n=369)
BMI, body mass index; ELSA, The English Longitudinal Study of Ageing. 
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examining the association between smoking and 
polypharmacy
The adjusted HR for polypharmacy and smoking was 1.06 
(0.86 to 1.29, P=0.56) (table 2), whereas the adjusted HR 
for hyperpolypharmacy and smoking was 0.98 (0.68 to 
1.39, P=0.89) (table 3). Both models failed to produce 
any statistically significant results.
examining the association between alcohol consumption and 
polypharmacy
Adjusted HRs for polypharmacy and hyperpolypharmacy 
were calculated using the participant’s alcohol consump-
tion data provided during the face-to-face interview. 
When compared with individuals who reported never 
drinking alcohol, the adjusted HR for participants who 
reported rarely consuming alcohol was 0.76 (0.61 to 
0.94, P=0.01) (table 2). This value decreased further to 
0.64 (0.52 to 0.78, p<0.01) in participants who reported 
drinking alcohol very frequently (table 2). The adjusted 
HRs for hyperpolypharmacy produced similar results. 
For participants who reported rarely consuming alcohol, 
the adjusted HR for hyperpolypharmacy was 0.70 (0.50 
to 0.99, P=0.05), when compared with individuals who 
reported never drinking alcohol (table 3); whereas the 
adjusted HR for hyperpolypharmacy in participants who 
reported drinking alcohol frequently was 0.39 (0.27 to 
0.55, p<0.01) (table 3). All adjusted HRs for polyphar-
macy and hyperpolypharmacy, in relation to self-reported 
alcohol consumption, were statistically significant.
DIsCussIOn
This study confirms that increasing age and the presence 
of chronic health conditions are associated with poly-
pharmacy prevalence, but also that obesity and lower 
wealth are significantly associated with polypharmacy. 
Frequent alcohol consumption is inversely associated 
with polypharmacy prevalence. Results from previous 
studies, which have investigated the influence of ageing 
and chronic health conditions on polypharmacy preva-
lence, complement our findings.19 22 23
In the existing literature, few studies have investi-
gated whether polypharmacy prevalence is associated 
with wealth or BMI.24 25 One study conducted in Rome, 
analysed a national prescription database and a multi-
variate model was used to identify participant character-
istics which influenced polypharmacy prevalence.24 The 
authors concluded that individuals living in lower socio-
economic areas are 33% more likely to experience poly-
pharmacy compared with individuals living in higher 
socioeconomic areas. In our study, participants were 
allocated to one of five wealth quintiles, based on their 
wealth index scores. Participants living in the lowest 
wealth quintiles were 28% more likely to experience 
polypharmacy and twice as likely to experience hyper-
polypharmacy, when compared with participants living 
in the highest wealth quintile. Our findings show that 
lower wealth is significantly associated with an increase in 
polypharmacy and hyperpolypharmacy prevalence. This 
finding is important because the latest figures published 
by the Office of National Statistics25 show that wealth 
inequalities across the UK have begun to rise again, after 
a decade-long decline. There is also evidence to suggest 
that the incidence of chronic health conditions and 
multimorbidities is highest among individuals residing 
in deprived areas.26 27 The aforementioned individuals 
are likely to require multiple medications to manage 
or treat their chronic conditions and thus, providing 
support for the association between lower wealth and 
polypharmacy.
Our multivariate model also revealed that obesity 
(BMI ≥30 kg/m2) was another factor associated with 
polypharmacy and hyperpolypharmacy prevalence. This 
finding was statistically significant. The same association 
was identified during another study; however, the authors 
did not comment on the statistical significance of their 
results, nor did they conduct any further research into the 
association.28 Identifying the association between poly-
pharmacy and obesity is also important because obesity 
has become a major public health concern in England. 
Assuming the current obesity epidemic continues as 
predicted, the prevalence of polypharmacy and hyper-
polypharmacy among older people in England, is likely 
to follow suit.29
This study found no statistically significant association 
between smoking and polypharmacy. Similarly, there were 
no statistically significant association between smoking 
and hyperpolypharmacy. Our findings are supported by 
Rajska-Neumann et al8 and Henderson et al.30 However, 
another study reports that smoking is inversely associated 
with polypharmacy (adjusted OR 0.42; 95% CI 0.33 to 
0.53).31
Frequent alcohol consumption in the past year was 
inversely associated with polypharmacy and hyperpoly-
pharmacy prevalence. This finding is consistent with 
previous work, involving ELSA, which reported that 
self-reported alcohol consumption (even at high levels) 
was not related to poor self-rated health.32 33 The alcohol 
findings in this current study could be explained by the 
sick quitter hypothesis, where individuals stop or reduce 
their alcohol consumption due to illness.34 However, 
Rimm and Moats35 conclude that the sick quitter hypoth-
esis has been refuted by a wide range of evidence. The 
inverse association between alcohol consumption and 
polypharmacy was also detected by Incalzi et al,31 although 
they appear to discount a genuine association and rather 
attribute this to bias (ie, patients in better health are less 
motivated to correct unhealthy habits).
Finally, most of the existing literature suggest that 
women take more medications compared with men; 
however, our study found that there was no statistically 
significant difference in polypharmacy and hyperpoly-
pharmacy prevalence between men and women.36–38 Pan 
et al39 provide support for our findings and concluded 
that the female sex is not significantly associated with an 
increased polypharmacy prevalence.
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To our knowledge this is the first study which has used 
medication data, from a large representative sample of 
older adults, to determine whether lower wealth, obesity, 
smoking, alcohol consumption, in addition to increasing 
age and the presence of chronic health conditions, 
are associated with polypharmacy and hyperpolyphar-
macy prevalence in primary care. All analysed data were 
obtained using standardised data collection methods and 
validated data collection tools. Also, this study used a 
large number of covariates, which reduced the impact of 
confounders and minimised study bias.
This study has several limitations. Actual medication use 
among participants may have been higher than recorded 
medication use for several reasons. First, participants were 
asked about their prescribed medications; however, medi-
cations purchased without prescription, for example, 
weak analgesics or antihistamines, were not recorded. 
Second, prescribed medications were coded according 
to BNF chapter and subsection. It was assumed that each 
code represented a single active ingredient; however, 
several combination drugs, for example, co-amilofruse 
and co-amilozide, were also represented by a single code. 
Furthermore, when the nurse enquired about prescribed 
medications, they asked the following question: ‘Are you 
taking or using any medications, pills, syrups, ointments, 
puffers or injections prescribed to you by a doctor or a 
nurse?’19 This question refers to some medicinal formu-
lations, but the list is not exhaustive. Thus, a participant 
using eye drops or wearing a transdermal patch may not 
have reported this medication as the formulation was not 
explicitly stated in the question. Consequently, polyphar-
macy and hyperpolypharmacy prevalence may have been 
underestimated in this study.
To obtain data about prescribed medications, smoking 
habits and alcohol consumption, participants were asked 
to self-report. This method of data collection relies on all 
participants accurately and truthfully recalling informa-
tion to prevent bias.40 The risk of recall bias associated 
with prescribed medication information was minimised 
by the nurse because participants were asked to show 
their medication containers to verify their responses. 
However, it was not possible to minimise the risk of recall 
bias associated with the other covariates. Participants 
also reported information about chronic health condi-
tions; however, the associations between specific health 
conditions, multimorbidity and polypharmacy were not 
examined in this study. Finally, it is not possible to deter-
mine the direction of causality from our data, due to the 
cross-sectional nature of this study.
COnClusIOn
This study has identified that lower wealth, obesity, 
increasing age and the presence of chronic health 
conditions are all associated with polypharmacy and 
hyperpolypharmacy prevalence, among older people in 
primary care. An inverse relationship between frequent 
alcohol consumption and polypharmacy prevalence was 
also established. In the future, the effect of obesity and 
lower wealth on polypharmacy and hyperpolypharmacy 
prevalence is likely to become more pronounced, as the 
gap in UK wealth inequalities begins to widen again and 
the UK obesity epidemic continues. Future exploratory 
work is required to determine the causation behind these 
associations.
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